OptimizeRx Posts 20c Adjusted EPS for Third Quarter
OPRX sits 96% above its 52-week low of $4.54 on elevated volume (1.8× avg).
Summary
OptimizeRx reported third-quarter adjusted earnings of 6 cents a share, per Dow Jones Newswires, with revenue of USD 21.6 Million versus an IBES estimate of USD 21.2 Million. The print lands against a baseline where the company had already cut its Q1 net loss sharply and turned an operating profit, so a positive adjusted EPS figure extends that improving profit trend. For a company of this size, a 6-cent quarterly adjusted EPS is a meaningful number and the first hard read on Q3 profitability. Sales fell on contracted revenue, and the company lowered its annual revenue outlook while projecting 2026 revenue of $87M-$93M.
At the time of this announcement, OPRX was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.9M. The 52-week trading range was $4.54 to $16.84. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.